ReviewEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2014
Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species.
Review in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 128 citations in OpenAlex.
- Pooled it
- Clinical study on empirical and diagnostic-driven (pre-emptive) therapy of voriconazole in severe aplastic anaemia patients with invasive fungal disease after intensive immunosuppressive therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2021Trial
- Clinical Case Report on the Use of Rezafungin inMicroorganisms · 2026Article
- Cost-Effectiveness of Once Weekly Rezafungin for the Treatment of Invasive Candidiasis in the United Kingdom.Mycoses · 2026Article
- Antifungal Resistance Surveillance: Insights From National Mycology Reference Centers and Expert Mycology Laboratories.Open forum infectious diseases · 2026Article
- Assessment of the Impact of Antimicrobial Photodynamic Therapy Using a 635 nm Diode Laser and Toluidine Blue on the Susceptibility of Selected Strains ofMicroorganisms · 2025Article
- Incidence and Risk Factors for Invasive Fungal Infection in Patients with Hematological Malignancies at a Tertiary Hospital in Malaysia.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- Antifungal Policy and Practice Across Five Countries: A Qualitative Review.Journal of fungi (Basel, Switzerland) · 2025Review
- Antifungal and anti-biofilm effects of hydrazone derivatives onJournal of enzyme inhibition and medicinal chemistry · 2024Article
- Adaptation to Sodium Hypochlorite and Potassium Permanganate May Lead to Their Ineffectiveness AgainstPharmaceuticals (Basel, Switzerland) · 2024Article
- Strain heterogeneity in a non-pathogenic Aspergillus fungus highlights factors associated with virulence.Communications biology · 2024Article
- Promoting antifungal stewardship through an antifungal multidisciplinary team in a paediatric and adult tertiary centre in the UK.JAC-antimicrobial resistance · 2024Article
- Unmasking the Antifungal Activity ofJournal of fungi (Basel, Switzerland) · 2024Article
- Strain heterogeneity in a non-pathogenic fungus highlights factors contributing to virulence.bioRxiv : the preprint server for biology · 2024Article
- In Vitro Assessment of Antifungal and Antibiofilm Efficacy of Commercial Mouthwashes againstAntibiotics (Basel, Switzerland) · 2024Article
- A case ofIDCases · 2024Article
- A lateral flow immunoassay for the rapid identification ofFrontiers in microbiology · 2024Article
- Topical Delivery of Terbinafine HCL Using Nanogels: A New Approach to Superficial Fungal Infection Treatment.Gels (Basel, Switzerland) · 2023Article
- Review
- Invasive candidiasis: current clinical challenges and unmet needs in adult populations.The Journal of antimicrobial chemotherapy · 2023Review
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive fungal diseases (IFDs) have been widely studied in recent years, largely because of the increasing population at risk. Aspergillus and Candida species remain the most common causes of IFDs, but other fungi are emerging. The early and accurate diagnosis of IFD is critical to outcome and the optimisation of treatment. Rapid diagnostic methods and new antifungal therapies have advanced disease management in recent years. Strategies for the prevention and treatment of IFDs include prophylaxis, and empirical and pre-emptive therapy. Here, we review the available primary literature on the clinical and economic burden of IFDs in Europe from 2000 to early 2011, with a focus on the value and outcomes of different approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.